US OptionsDetailed Quotes
PRQR241220C7500
- 0.05
- 0.000.00%
15min DelayTrading Nov 19 09:43 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume3 Open Interest7.50Strike Price0.00Turnover181.71%IV116.95%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0805Delta0.0920Gamma69.60Leverage Ratio-0.0051Theta0.0001Rho5.60Eff Leverage0.0013Vega
ProQR Therapeutics Stock Discussion
Sign in to post a comment
1
6
$ProQR Therapeutics (PRQR.US)$ 300%+ let’s she go
2
$Lightbridge (LTBR.US)$ $Biodexa Pharmaceuticals (BDRX.US)$ $Fangdd Network (DUO.US)$ $Connexa Sports Technologies (YYAI.US)$ $Arqit Quantum (ARQQ.US)$ $SAIHEAT (SAIH.US)$ $Wave Life Sciences (WVE.US)$ $ProQR Therapeutics (PRQR.US)$ $Carmell (CTCX.US)$ $Korro Bio (KRRO.US)$ $Quoin Pharmaceuticals (QNRX.US)$ $Versus Systems (VS.US)$ $Santech Holdings (STEC.US)$ $180 Life Sciences (ATNF.US)$
1
1
$ProQR Therapeutics (PRQR.US)$
big offering watchout
big offering watchout
$ProQR Therapeutics (PRQR.US)$
NEWS
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical data for its AX-0810 pipelin...
NEWS
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical data for its AX-0810 pipelin...
ProQR Therapeutics' short term liquidity and more cash than debt suggest it can manage its debt safely. Its 38% revenue growth is a positive sign, indicating potential for further strong growth.
$ProQR Therapeutics (PRQR.US)$ load the dip
No comment yet
Stock_Drift OP Krystian 1983 : What’s down 30%?
Stock_Drift OP Krystian 1983 : Ask the market. I don’t control it, just report it.
Stock_Drift OP Krystian 1983 : Like a lot of them. $Maxeon Solar Technologies (MAXN.US)$ for example.
Krystian 1983 Stock_Drift OP : I Will try to report That
thanks you
Stock_Drift OP Krystian 1983 : Sorry. The market does what it does, even the best DD doesn’t always produce.
View more comments...